A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status

Clinical Medicine Insights. Oncology
Ying-Wen SuPo-Sheng Yang

Abstract

The clinical benefit of adding platinum to adjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) has not been well investigated, although it was associated an improved response rate in neoadjuvant setting. We retrospectively analyzed the time to tumor progression (TTP) and overall survival (OS) of patients with resected stage I-III TNBC who were treated with or without cisplatin-containing chemotherapy (CisCT or noCisCT) during 2004 and 2010. Of 129 patients, 25 received CisCT. In univariate analysis, the mean TTP for CisCT and noCisCT was 4.42 and 5.88 years, respectively (P = .004). The mean OS for CisCT and noCisCT was 6.76 and 9.63 years, respectively (P = .24). After adjusting for other clinicopathologic factors, only clinical stage II/III disease was independently associated with worse OS. The adjusted hazard ratio for CisCT was 1.48 (P = .46) and was not statistically significant. In this small retrospective study, adding cisplatin to adjuvant chemotherapy for early TNBC with unknown BRCA mutation status did not benefit OS.

References

Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Dec 13, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Chad A LivasyCharles M Perou
Oct 24, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Emad A RakhaIan O Ellis
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Oct 12, 2007·The New England Journal of Medicine·Daniel F HayesUNKNOWN Cancer and Leukemia Group B (CALGB) Investigators
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomasz ByrskiSteven Narod
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel P SilverJudy E Garber
Jun 4, 2010·The New England Journal of Medicine·Sandra M SwainNorman Wolmark
Jul 16, 2010·International Journal of Clinical Oncology·Yutaka Yamamoto, Hirotaka Iwase
Jan 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ana M Gonzalez-AnguloFunda Meric-Bernstam
Feb 10, 2011·The Oncologist·Clifford A Hudis, Luca Gianni
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Dec 8, 2011·Breast Cancer Research and Treatment·Aoife J LoweryKarl J Sweeney
Oct 4, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P Boyle
Apr 8, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven J IsakoffLeif W Ellisen
Aug 10, 2015·The Breast : Official Journal of the European Society of Mastology·Daniel G Stover, Eric P Winer
Aug 19, 2015·BMC Medicine·Jesus AnampaJoseph A Sparano
Dec 15, 2015·Journal of the National Comprehensive Cancer Network : JNCCN·William J GradisharRashmi Kumar

❮ Previous
Next ❯

Citations

May 31, 2019·Oncoimmunology·Irina LarionovaJulia Kzhyshkowska
Aug 19, 2020·International Journal of Molecular Sciences·Andrew SulaimanLisheng Wang

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02445391

Software Mentioned

GeparSixto

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.